Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.
New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.
During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- In Stroke, No Clear Benefit for Head Positioning